Abstract: A delivery device for a collapsible prosthetic heart valve, the delivery device including an inner shaft, a distal sheath disposed about a portion of the inner shaft and forming a compartment with the inner shaft, the compartment being adapted to receive the prosthetic heart valve, the inner shaft and the distal sheath being movable relative to one another, and a handle including a frame having a longitudinal axis, a proximal end and a distal end, the handle further including a deployment actuator and a hub, each of the deployment actuator and the hub being independently capable of opening and closing the compartment, the hub further including a hub actuator coupled to the inner shaft.

Abstract: A delivery device for a collapsible prosthetic heart valve, the delivery device including an inner shaft, a distal sheath disposed about a portion of the inner shaft and forming a compartment with the inner shaft, the compartment being adapted to receive the prosthetic heart valve, the inner shaft and the distal sheath being movable relative to one another, and a handle including a frame having a longitudinal axis, a proximal end and a distal end, the handle further including a deployment actuator and a hub, each of the deployment actuator and the hub being independently capable of opening and closing the compartment, the hub further including a hub actuator coupled to the inner shaft.

Abstract: A delivery device 1010 for a collapsible prosthetic heart valve 200, the delivery device including an inner shaft 1026, a distal sheath 1024 disposed about a portion of the inner shaft and forming a compartment 1023 with the inner shaft, the compartment being adapted to receive the prosthetic heart valve, the inner shaft and the distal sheath being movable relative to one another, and a handle 1020 including a frame 1030 having a longitudinal axis, a proximal end and a distal end, the handle further including a deployment actuator 1021 and a hub 1100, each of the deployment actuator and the hub being independently capable of opening and closing the compartment, the hub further including a hub actuator 1600 coupled to the inner shaft.

Abstract: A delivery device for a collapsible prosthetic heart valve, the delivery device including an inner shaft, a distal sheath disposed about a portion of the inner shaft and forming a compartment with the inner shaft, the compartment adapted to receive the valve, the inner shaft and the distal sheath being movable relative to one another, and a handle including a frame having a longitudinal axis, a proximal end and a distal end, the handle including a deployment actuator and a hub, the deployment actuator and the hub being independently capable of opening and closing the compartment, a resheathing lock configured to alert a user of a position of the distal sheath and to impede movement of the distal sheath, and an indicator disposed on the frame and capable of showing an extent of deployment of the valve.

Abstract: A syringe holding assembly for filling a syringe with medication includes a block that has a first well therein to insertably receive a medication bottle. The block has a second well therein to insertably receive a syringe. The first well is aligned with the second well to align the syringe with the medication bottle. In this way a user with limited hand dexterity is assisted to fill the syringe with medication. An adapter is provided to receive a vial. The adapter is removably positioned in the first well thereby facilitating the vial to be aligned with the syringe.

Abstract: A syringe holding assembly for filling a syringe with medication includes a block that has a first well therein to insertably receive a medication bottle. The block has a second well therein to insertably receive a syringe. The first well is aligned with the second well to align the syringe with the medication bottle. In this way a user with limited hand dexterity is assisted to fill the syringe with medication. An adapter is provided to receive a vial. The adapter is removably positioned in the first well thereby facilitating the vial to be aligned with the syringe.

Abstract: A delivery device 1010 for a collapsible prosthetic heart valve 200, the delivery device including an inner shaft 1026, a distal sheath 1024 disposed about a portion of the inner shaft and forming a compartment 1023 with the inner shaft, the compartment being adapted to receive the prosthetic heart valve, the inner shaft and the distal sheath being movable relative to one another, and a handle 1020 including a frame 1030 having a longitudinal axis, a proximal end and a distal end, the handle further including a deployment actuator 1021 and a hub 1100, each of the deployment actuator and the hub being independently capable of opening and closing the compartment, the hub further including a hub actuator 1600 coupled to the inner shaft.

Abstract: A delivery device for a collapsible prosthetic heart valve, the delivery device including an inner shaft, a distal sheath disposed about a portion of the inner shaft and forming a compartment with the inner shaft, the compartment adapted to receive the valve, the inner shaft and the distal sheath being movable relative to one another, and a handle including a frame having a longitudinal axis, a proximal end and a distal end, the handle including a deployment actuator and a hub, the deployment actuator and the hub being independently capable of opening and closing the compartment, a resheathing lock configured to alert a user of a position of the distal sheath and to impede movement of the distal sheath, and an indicator disposed on the frame and capable of showing an extent of deployment of the valve.

Abstract: Disclosed are compounds of formula (I): wherein R1, R2, R3, R4, and R5 have the meanings given in the description, and to salts thereof, pharmaceutical compositions comprising said compounds and the use thereof as protein kinase inhibitors.

Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, and R5 have the meanings given in the description, and to salts thereof, pharmaceutical compositions comprising said compounds and the use thereof as protein kinase inhibitors.

Abstract: The present invention discloses and claims compounds of formula (I) wherein M is N, and K and L are each C with the remaining substituents further defined herein. These compounds are effective as inhibitors of human casein kinase I?, and as such are useful in the treatment of central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.

Abstract: The present invention discloses and claims compounds of formula (I) wherein M is N, and K and L are each C with the remaining substituents further defined herein. These compounds are effective as inhibitors of human casein kinase I?, and as such are useful in the treatment of central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.

Abstract: The present invention discloses and claims compounds of formula (I) as inhibitors of human casein kinase IF, and methods of using said compounds of formula (I) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.

Abstract: Disclosed are compounds of formula (I): wherein R1, R2, R3, R4, and R5 have the meanings given in the description, and to salts thereof, pharmaceutical compositions comprising said compounds and the use thereof as protein kinase inhibitors.

Abstract: The present invention discloses and claims compounds of formula (I) and formula (II) as inhibitors of human casein kinase I?, and methods of using said compounds of formula (I) and formula (II) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. The R-group substituents are defined herein and pharmaceutical compositions comprising compounds of formula (I) or formula (II) are also disclosed and claimed.

Abstract: The present invention relates to methods for treating a patient suffering from a disease or disorder of the central nervous system associated with the disturbance of the human circadian clock that are ameliorated by inhibition of casein kinase I? activity such as, for example, mood disorders including major depressive disorder, bipolar I disorder and bipolar II disorder, and sleep disorders including circadian rhythm sleep disorders such as, for example, shift work sleep disorder, jet lag syndrome, advanced sleep phase syndrome and delayed sleep phase syndrome, comprising administering to said patient a therapeutically effective amount of a compound of formula I.

Abstract: A proactive and unifying systems-based method for total emergency management supported by an information technology architecture. The use of an embedded process for collaboration among a myriad of agencies fulfills newly recognized critical needs for interconnectivity and coordinated relationships among the public, private, nonprofit, and not-for-profit sectors in community preparedness, improved camaraderie among members of separate agencies, and a coordinated, integrated, and synchronized emergency response. Knowing and agreeing upon the actions that precede and succeed an integrating action among entities is the critical output of the synchronization matrix process for the present invention. The concept of tying these integrating actions to hazard actions and to decision points, so that timing of alert and notification, population protection, and response actions can be assessed against what needs to be initiated and when, serves to minimize community impacts from routine and catastrophic emergencies.

Abstract: The present invention discloses and claims compounds of formula (I) as inhibitors of human casein kinase IF, and methods of using said compounds of formula (I) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.

Abstract: This invention relates to compounds which are inhibitors of elastase, particularly human neutrophil elastase. The inhibitors are short, synthetic peptides in which the P2 moiety is substituted with various nitrogen-containing heterocyclic groups. As inhibitors of human neutrophil elastase, the compounds are useful in the treatment of a patient afflicted with a neutrophil associated inflammatory disease.

Abstract: This invention relates to compounds which are inhibitors of elastase, particularly human neutrophil elastase. The inhibitors are short, synthetic peptides in which the P2 moiety is substituted with various nitrogen-containing heterocyclic groups. As inhibitors of human neutrophil elastase, the compounds are useful in the treatment of a patient afflicted with a neutrophil associated inflammatory disease.